Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).

Jorge Cortes, MD, Susan O’Brien, MD, Elias Jabbour, MD, Alexandra Ferrajoli, MD, Gautam Borthakur, MD, Jan Burger, MD, William Wierda, MD, Guillermo Garcia-Manero, MD, Michelle Thomas, RN, Laurie Letvak, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 29.

https://doi.org/10.1182/blood.V110.11.29.29

Published: 2007

Journal Articles

Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Alessandra Ferrajoli, MD, Srdan Verstovsek, MD, PhD, Dan Jones, MD, Laurie Letvak, MD, Richard Champlin, MD, Jorge Cortes, MD, Susan O’Brien, MD

Blood (2007) 110 (11): 9.

https://doi.org/10.1182/blood.V110.11.9.9

Published: 2007

Journal Articles

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

Carolyn Blasdel, MA, RN, FNP, Yanfeng Wang, PhD, Theodore Lagattuta, BS, Brian Druker, MD, Laurie Letvak, MD, Merrill Egorin, MD FACP

Blood (2006) 108 (11): 4820.

https://doi.org/10.1182/blood.V108.11.4820.4820

Published: 2006

Journal Articles

Preliminary Activity of Nilotinib (AMN107), a Novel Selective Potent Oral Bcr-Abl Tyrosine Kinase Inhibitor, in Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Phase Chronic Myelogenous Leukemia (CML-CP).

Elias Jabbour, MD, Jorge Cortes, MD, Francis Giles, MD, Susan O’Brien, MD, Laurie Letvak, MD, Hagop Kantarjian, MD

Blood (2006) 108 (11): 2172.

https://doi.org/10.1182/blood.V108.11.2172.2172

Published: 2006

Journal Articles

Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Stefan Faderl, MD, Jorge Cortes, MD, Susan O’Brien, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, Steven Kornblau, MD, PhD, Michael Andreeff, MD, PhD, Miloslav Beran, MD, PhD, Srdan Verstovsek, MD, PhD, Sherry Pierce, RN, Laurie Letvak, MD, August Salvado, MD, Richard Champlin, MD, Hagop Kantarjian, MD

Blood (2005) 106 (11): 1830.

https://doi.org/10.1182/blood.V106.11.1830.1830

Published: 2005

Journal Articles

Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Stefan Faderl, MD, Jorge Cortes, MD, Susan O’Brien, MD, Francis Giles, MD, Guillermo Garcia, MD, Steven Kornblau, MD, Michael Andreeff, MD, PhD, Miloslav Beran, MD, PhD, Srdan Verstovsek, MD, PhD, Sherry Pierce, RN, Laurie Letvak, MD, August Salvado, MD, Richard Champlin, MD, Hagop Kantarjian, MD

Blood (2004) 104 (11): 2738.

https://doi.org/10.1182/blood.V104.11.2738.2738

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).

Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

Preliminary Activity of Nilotinib (AMN107), a Novel Selective Potent Oral Bcr-Abl Tyrosine Kinase Inhibitor, in Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Phase Chronic Myelogenous Leukemia (CML-CP).

Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

Update search

Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).

Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

Preliminary Activity of Nilotinib (AMN107), a Novel Selective Potent Oral Bcr-Abl Tyrosine Kinase Inhibitor, in Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Phase Chronic Myelogenous Leukemia (CML-CP).

Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only